Johnson & Johnson Innovation Spotlight 2021

Asia Pacific

Since its establishment in 2013, Johnson & Johnson Innovation has supported and collaborated with the Asia Pacific ecosystem to curate and cultivate the best early-stage life science, consumer health and technology innovation for patients and consumers across the world.

Dan Wang

quote open

Inspiring ideas and disruptive innovation can come from anywhere. We all benefit from collaboration, which is why we continue to bring meaningful solutions and flexible approaches to support innovators at any stage by leveraging our global network of resources, scale, reach and expertise to advance health in the region and around the world.

quote close

Dan Wang, MD, MPH, MBA

Head of Johnson & Johnson Innovation Asia Pacific

Accelerating Innovation in Asia Pacific

 

Shanghai Location

Through our regional hub, based out of Shanghai, we are deeply embedded within and tightly connected to the external early innovation ecosystem around the world, with offices located in Tokyo, Seoul, Singapore and Hong Kong SAR.

 

LocationsAsia Pacific Footprint and co-creation

Co-Creation model

We leverage innovative business models and deploy a suite of capabilities to meet the diverse needs of entrepreneurs, scientists, health technology innovators and emerging companies from across the pharmaceutical, medical device and consumer health sectors.

Flexible and customized partnership models allow us to create the right deal to best suit the technology and the innovator with whom we are working, so that together we can have a meaningful impact on human health around the world.

Strategic Therapeutic Areas

Strategic therapeutic areas

 

Single Point of Entry for Innovation

We're a single-entry point into a sweeping set of super-charged solutions. Early-stage innovation incubation. Creative deal-making. Strategic deployment of venture capital. Johnson & Johnson Innovation's diverse team of science and technology experts in the Asia Pacific region works with entrepreneurs to flex and shape their solutions to bridge scientific gaps and unlock meaningful improvements in human health.

Depending on where an idea is in its life cycle, integrated Johnson & Johnsons Innovation teams make it easy for our collaborators and partners to tap into our broad and unique range of tools and capabilities, including:

JLABS @ Shanghai: Life Science Incubator

Opened in 2019 to accommodate more than 50 life sciences and healthcare start-ups, JLABS @ Shanghai is more than just the combinations of shared and private lab and office spaces, equipment, value-added solutions, operational support, education and business services - it provides access to an ecosystem that could help transform ideas from concept to reality.

JLABS @ Shanghai Life Science Incubator

JJDC: Funding and Equity Investment

JJDC is the strategic venture capital arm of Johnson & Johnson with a 49-year legacy. Our experienced investors work to identify transformational ideas in the external ecosystem - from start-up to Series B and beyond - and through investment and advice, help companies to realize their ideas into solutions for patients.

 

JJDC Funding and Equity Investment

 

Cross-Sector Innovation

Cross-Sector Innovation

The Lung Cancer Initiative at Johnson & Johnson in China (LCI China)

Established in 2018, LCI China is an integral part of Lung Cancer Initiative at Johnson & Johnson and is made up of a dedicated team focused on the prevention, interception and cure of lung cancer. With expertise across clinical, pharmaceutical, engineering, surgical and early detection sciences, the local team works in strong collaboration with Johnson & Johnson sector partners to advance critical programs.

World Without Disease Accelerator (WWDA)

The WWDA is focused on the discovery, development and delivery of disruptive products/technologies, business models and partnerships to advance the elimination of disease around the world. Working in conjunction with the LCI China team, the WWDA is comprised of entrepreneurial capability teams working to advance disease interception in targeted disease areas, with lung cancer as a key priority.

Early Stage Innovation Partnership in Action

At Johnson & Johnson Innovation Asia Pacific, we take a tailored approach to different markets in the region based on the strengths of the innovation ecosystems. Below are some examples of successful partnerships we have made in life science hot spots in the region.

In 2018, in partnership with A*STAR, we launched a world without disease grant call to support life science innovation in Singapore.
Janssen began its strategic partnership with HitGen in 2016 in China to screen HitGen's DNA Encoded Libraries (DELs) for a series of targets in different therapeutic areas.
Since 2018, Johnson & Johnson Vision has been working with PlyU to study how to control Myopia (nearsightedness) progression in children aged -13 years.
Insilico Medicine is a JLABS @ Shanghai resident company that specializes in AI-based drug discovery.
Through our long-standing collaboration with A*STAR, we have been able to develop many meaningful and exciting collaborations with Singapore-based companies, including one MiRXES, its spin-off Singapore-based biotechnology company that specializes in microRNA discovery and diagnostics.
We have been working with PeptiDream since 2017 to leverage PeptiDream's proprietary Peptide Discovery Platform
Together with T&R Biofab, a Korea-based 3D bioprinting company, Ethicon Inc. and Johnson & Johnson 3D printing will collaborate on developing innovative 3D bio-printed soft tissue reinforcement scaffolds (STRS), based on T&R Biofab's platform technology using polymer, in sity extracellular matrix (ECM) proteins and 3D bioprinting.
As a part of our new business model collaborations, Johnson & Johnson Medical (Shanghai) Limited (JJMS) will be working with Taikang (Tk.cn), a Chinese online healthcare sports injury-related insurance package.
Together with Janssen R&D, Takeda Pharmaceutical and Shonan Health Innovation Park (Shonan iPark), we launched a World Without Disease Call-for-Proposal in Japan and selected five awardees in the research areas of lung cancer, myopia, infant/child health and neuroscience.
Urgaze launched a new UV imaging device - the UVLOOK Mini UV camera - that converts UV reflection into images visible to the human eye, all from your smartphone.

 

Connect With Us

Are you working on an early-stage innovation that has the potential to transform into the next breakthrough idea or solution?

If it falls under any of the strategic therapeutic areas mentioned above, reach out to our Sourcing Lead in AP, Charleen Nien at CNien@its.jnj.com , with your non-confidential company/research introduction. We look forward to hearing from you.

Download one pager